Biology of Castration-Recurrent Prostate Cancer

Urologic Clinics of North America

Volumn 39, Issue 4, 2012, Pages 435-452

  Azzouni, Faris ^a   Mohler, James ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Biology; Castration recurrent; Castration resistant; Mechanism; Prostate cancer

Indexed keywords

ABIRATERONE; ALANINE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; ERLOTINIB; FINASTERIDE; FLUTAMIDE; GALETERONE; GELDANAMYCIN; HISTIDINE; HYDROCORTISONE; KETOCONAZOLE; LAPATINIB; ORTERONEL; PRASTERONE; PROSTATE SPECIFIC ANTIGEN; ROMIDEPSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; THREONINE; TOK 01; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; AMINO ACID SUBSTITUTION; ANDROGEN DEPRIVATION THERAPY; CANCER PALLIATIVE THERAPY; CASTRATION RECURRENT PROSTATE CANCER; DRUG TARGETING; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; METASTASIS POTENTIAL; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; TESTOSTERONE; TRANSCRIPTIONAL ACTIVATION;

EID: 84867663093     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2012.07.002     Document Type: Review

References (136)

1. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002, 167(2 Pt 2):948-951.
2. Chen Y., Clegg N.J., Scher H.I. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009, 10(10):981-991.
3. Gelmann E.P. Molecular biology of the androgen receptor. J Clin Oncol 2002, 20(13):3001-3015.
4. Simental J.A., Sar M., Lane M.V., et al. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991, 266(1):510-518.
5. Jenster G., van der Korput H.A., Trapman J., et al. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 1995, 270:7341-7346.
6. Platz E.A., Rimm E.B., Willett W.C., et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000, 92(24):2009-2017.
7. Stanford J.L., Just J.J., Gibbs M., et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997, 57(6):1194-1198.
8. Zeegers M.P., Kiemeney L.A., Nieder A.M., et al. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?. Cancer Epidemiol Biomarkers Prev 2004, 13(11 Pt 1):1765-1771.
9. Bratt O., Borg A., Kristoffersson U., et al. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999, 81(4):672-676.
10. Correa-Cerro L., Wohr G., Haussler J., et al. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 1999, 7(3):357-362.
11. Walcott J.L., Merry D.E. Trinucleotide repeat disease. The androgen receptor in spinal and bulbar muscular atrophy. Vitam Horm 2002, 65:127-147.
12. Hard T., Kellenbach E., Boelens R., et al. Solution structure of the glucocorticoid receptor DNA-binding domain. Science 1990, 249:157-160.
13. Schoenmakers E., Alen P., Verrijdt G., et al. Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains. Biochem J 1999, 341(Part 3):515-521.
14. Gioeli D., Ficarro S.B., Kwiek J.J., et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 2002, 277:29304-29314.
15. Fu M., Rao M., Wang C., et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 2003, 23:8563-8575.
16. Zhou Z.X., Kemppainen J.A., Wilson E.M. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 1995, 9(5):605-615.
17. Sack J.S., Kish K.F., Wang C., et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A 2001, 98:4904-4909.
18. Bourguet W., Ruff M., Chambon P., et al. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-a. Nature 1995, 375:377-382.
19. Pratt W.B., Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997, 18:306-360.
20. Prescott J., Coetzee G.A. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 2006, 231:12-19.
21. Li J., Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009, 63(2):142-148.
22. Heinlein C.A., Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002, 23(2):175-200.
23. Visakorpi T., Hyytinen E., Koivisto P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995, 9(4):401-406.
24. Koivisto P., Kononen J., Palmberg C., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997, 57(2):314-319.
25. Palmberg C., Koivisto P., Kakkola L., et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000, 164(6):1992-1995.
26. Ford O.H., Gregory C.W., Kim D., et al. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003, 170(5):1817-1821.
27. Attard G., Swennenhuis J.F., Olmos D., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69(7):2912-2918.
28. Leversha M.A., Han J., Asgari Z., et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009, 15(6):2091-2097.
29. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004, 164(1):217-227.
30. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10(1):33-39.
31. Nelson J.B., Chan-Tack K., Hedican S.P., et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996, 56:663-668.
32. Nelson J.B., Hedican S.P., George D.J., et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1:944-949.
33. Lee J.G., Zheng R., McCafferty-Cepero J.M., et al. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Mol Carcinog 2009, 48(2):141-149.
34. Gregory C.W., Johnson R.T., Mohler J.L., et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001, 61(7):2892-2898.
35. Gregory C., He B., Johnson R., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001, 61:4315-4319.
36. Guo Z., Dai B., Jiang T., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006, 10:309-319.
37. Mahajan N.P., Liu Y., Majumder S., et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A 2007, 104:8438-8443.
38. Askew E.B., Gampe R.T., Stanley T.B., et al. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 2007, 282(35):25801-25816.
39. Deslypere J.P., Young M., Wilson J.D., et al. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol 1992, 88(1-3):15-22.
40. Mohler J.L., Gregory C.W., Ford O.H., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004, 10(2):440-448.
41. Montgomery R.B., Mostaghel E.A., Vessella R., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008, 68(11):4447-4454.
42. Thomas L., Lazier C., Gupta R., et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005, 63:231-239.
43. Godoy A., Kawinski E., Li Y., et al. 5α-Reductase 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 2011, 71(10):1033-1046.
44. Russell D.W., Wilson J.D. Steroid 5a-reductase: two genes/two enzymes. Annu Rev Biochem 1994, 63:25-61.
45. Titus M.A., Schell M.J., Lih F.B., et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005, 11(13):4653-4657.
46. Leon C., Locke J., Adomat H., et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010, 70:390-400.
47. Locke J., Guns E., Lubik A., et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008, 68(15):6407-6415.
48. Harper M.E., Pike A., Peeling W.B., et al. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 1974, 60(1):117-125.
49. Mohler J.L., Titus M.A., Wilson E.M. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011, 17(18):5844-5849.
50. Mohler J.L., Titus M.A., Bai S., et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011, 71(4):1486-1496.
51. Small E.J., Ryan C.J. The case for secondary hormonal therapies in the chemotherapy age. J Urol 2006, 176(6 Pt 2):S66-S71.
52. Shah S., Trump D., Sartor O., et al. Phase II study of dutasteride in recurrent prostate cancer during androgen-deprivation therapy. J Urol 2009, 181:621-626.
53. Azzouni F., Mohler J. Role of 5α-reductase inhibitors in prostate cancer prevention and treatment. Urology 2012, 79(6):1197-1205. [Epub 2012 Mar 23].
54. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364(21):1995-2005.
55. Ryan C.J., Smith M.R., Fong L., et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010, 28(9):1481-1488.
56. Feldman B., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001, 1(1):34-45.
57. Taplin M.E., Bubley G.J., Ko Y.J., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999, 59(11):2511-2515.
58. Fenton M.A., Shuster T.D., Fertig A.M., et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997, 3(8):1383-1388.
59. Terakawa T., Miyake H., Kumano M., et al. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells. Oncol Rep 2010, 24(5):1395-1399.
60. Veldscholte J., Ris-Stalpers C., Kuiper G.G., et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990, 173(2):534-540.
61. Veldscholte J., Berrevoets C.A., Ris-Stalpers C., et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992, 41(3-8):665-669.
62. Taplin M.E., Bubley G.J., Shuster T.D., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995, 332(21):1393-1398.
63. Taplin M.E., Rajeshkumar B., Halabi S., et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003, 21(14):2673-2678.
64. Greene S.L., Stockton P., Kozyreva O.G., et al. Molecular analysis of the androgen receptor using laser capture microdissection and direct sequencing. Cancer cell signalling: methods and protocols 2003, 287-302. Humana Press, Inc, Totowa (NJ). D.M. Terrian (Ed.).
65. McDonald S., Brive L., Agus D.B., et al. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res 2000, 60(9):2317-2322.
66. Zhao X.Y., Boyle B., Krishnan A.V., et al. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 1999, 162(6):2192-2199.
67. Zhao X.Y., Malloy P.J., Krishnan A.V., et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000, 6(6):703-706.
68. Hu R., Denmeade S.R., Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab 2010, 5(5):753-764.
69. Agoulnik I.U., Weigel N.L. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol 2008, 617:245-255.
70. Chmelar R., Buchanan G., Need E.F., et al. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int J Cancer 2007, 120(4):719-733.
71. Halkidou K., Gnanapragasam V.J., Mehta P.B., et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003, 22(16):2466-2477.
72. Majumder S., Liu Y., Ford O.H., et al. Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability. Prostate 2006, 66:1292-1301.
73. Agoulnik I.U., Vaid A., Bingman W.E., et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005, 65(17):7959-7967.
74. Agoulnik I.U., Vaid A., Nakka M., et al. Androgens modulate expression of TIF2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006, 66:10594-10602.
75. Yeh S., Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A 1996, 93(11):5517-5521.
76. Yeh S.-H., Miyamoto H., Shima H., et al. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A 1998, 95(10):5527-5532.
77. Wang L., Hsu C.L., Chang C. Androgen receptor corepressors: an overview. Prostate 2005, 63:117-130.
78. Agoulnik I.U., Krause W.C., Bingman W.E.I., et al. Repressors of androgen and progesterone receptor action. J Biol Chem 2003, 278:31136-31148.
79. Burd C.J., Petre C.E., Morey L.M., et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A 2006, 103:2190-2195.
80. Martinez E.D., Danielsen M. Loss of androgen receptor transcriptional activity at the G(1)/S transition. J Biol Chem 2002, 277:29719-29729.
81. Karvonen U., Janne O.A., Palvimo J.J., et al. Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion. Exp Cell Res 2006, 312(16):3165-3183.
82. Chen G., Nomura M., Morinago H., et al. Modulation of androgen receptor transactivation by FoxH1. A newly identified androgen receptor corepressor. J Biol Chem 2005, 280:36355-36363.
83. Belandia B., Powell S.M., Garcia-Pedrero J.M., et al. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol 2005, 25:1425-1436.
84. Yoon H.G., Wong J. The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor. Mol Endocrinol 2006, 20:1048-1060.
85. Berrevoets C.A., Umar A., Trapman J., et al. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). Biochem J 2004, 379(Part 3):731-738.
86. Jackson T.A., Richer J.K., Bain D.L., et al. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 1997, 11:693-705.
87. Liao G., Chen L.Y., Zhang A., et al. Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 2003, 278:5052-5061.
88. Miyamoto H., Rahman M.M., Chang C. Molecular basis for the antiandrogens withdrawal syndrome. J Cell Biochem 2004, 91:3-12.
89. Culig Z., Hobisch A., Cronauer M.V., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 54(20):5474-5478.
90. Hobisch A., Eder I.E., Putz T., et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998, 58(20):4640-4645.
91. Gregory C.W., Fei X., Ponguta L.A., et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 2004, 279(8):7119-7130.
92. Ueda T., Mawji N.R., Bruchovsky N., et al. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 2002, 277(41):38087-38094.
93. Krueckl S.L., Sikes R.A., Edlund N.M., et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004, 64(23):8620-8629.
94. George D.J., Halabi S., Shepard T.F., et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res 2005, 11(5):1815-1820.
95. Di Lorenzo G., Tortora G., D'Armiento F.P., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002, 8(11):3438-3444.
96. Lin H.K., Yeh S., Kang H.Y., et al. AKT suppresses androgen- induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A 2001, 98(13):7200-7205.
97. Yeh S., Lin H., Kang H., et al. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 1999, 96(10):5458-5463.
98. Zhou H., Li X., Meinkoth J., et al. AKT regulates cell survival and apoptosis at a post-mitochondrial level. J Cell Biol 2000, 151:483-494.
99. Craft N., Shostak Y., Carey M., et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999, 5(3):280-285.
100. Roy V., Perez E.A. Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist 2009, 14(11):1061-1069.
101. Ceraline J., Cruchant M.D., Erdmann E., et al. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer 2004, 108:152.
102. Libertini S.J., Tepper C.G., Rodriguez V., et al. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res 2007, 67:9001-9005.
103. Hu R., Dunn T.A., Wei S., et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009, 69(1):16-22.
104. Guo Z., Yang X., Sun F., et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009, 69(6):2305-2313.
105. De Marzo A.M., Platz E.A., Sutcliffe S., et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7(4):256-269.
106. Drachenberg D.E., Elgamal A.A., Rowbotham R., et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999, 41:127-133.
107. Rose-John S. Coordination of interleukin-6 biology by membrane bound and soluble receptors. Adv Exp Med Biol 2001, 495:145-151.
108. Azevedo A., Cunha V., Teixeira A.L., et al. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol 2011, 2(12):384-396.
109. Nadiminty N., Lou W., Lee S.O., et al. Stat3 activation of NF-κB p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci U S A 2006, 103:7264-7269.
110. Nadiminty N., Chun J.Y., Lou W., et al. NF-κB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen deprivation. Prostate 2008, 68:1725-1733.
111. Nadiminty N., Lou W., Sun M., et al. Aberrant activation of the androgen receptor by NF-κB2/p52 in prostate cancer cells. Cancer Res 2010, 70(8):3309-3319.
112. Narayanan B.A., Reddy B.S., Bosland M.C., et al. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: In vivo evidence. Clin Cancer Res 2007, 13:5965-5973.
113. Khor L.Y., Bae K., Pollack A., et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 2007, 8(10):912-920.
114. Colombel M., Symmans F., Gil S., et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol 1993, 143(2):390-400.
115. Liu A., Corey E., Bladou F., et al. Prostatic cell lineage markers: emergence of Bcl2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996, 65(1):85-89.
116. Gleave M., Tolcher A., Miyake H., et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999, 5(10):2891-2898.
117. Datta S., Brunet A., Greenberg M. Cellular survival: a play in three AKTs. Genes Dev 1999, 13(22):2905-2927.
118. Stambolic V., Suzuki A., de la Pompa J.L., et al. Negative regulation of PKB/AKT dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95(1):29-39.
119. Graff J.R., Konicek B.W., McNulty A.M., et al. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000, 275(32):24500-24505.
120. Debes J.D., Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004, 351(15):1488-1490.
121. Fixemer T., Remberger K., Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002, 53(2):118-123.
122. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001, 12(Suppl 2):S141-S144.
123. Bonkhoff H., Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 2009, 55:533-542.
124. Bonkhoff H., Fixemer T., Hunsicker I., et al. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 1999, 155:641-647.
125. Bonkhoff H., Fixemer T., Hunsicker I., et al. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate 2001, 48:285-291.
126. Fixemer T., Remberger K., Bonkhoff H. Differential expression of the estrogen receptor beta (ER beta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003, 54:79-87.
127. Setlur S.R., Mertz K.D., Hoshida Y., et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008, 100:815-825.
128. Ricke W., Wang Y., Cunha G. Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 2007, 75:871-882.
129. Collins A.T., Habib F.K., Maitland N.J., et al. Identification and isolation of human prostate epithelial stem cells based on α2β1-integrin expression. J Cell Sci 2001, 114:3865-3872.
130. Collins A.T., Berry P.A., Hyde C., et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65(23):10946-10951.
131. Leong K.G., Wang B.E., Johnson L., et al. Generation of a prostate from a single adult stem cell. Nature 2008, 456(7223):804-808.
132. Pienta K., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006, 12(6):1665-1671.
133. Chi K.N., Bjartell A., Dearnaley D., et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009, 56(4):594-605.
134. Attard G., Richards J., de Bono J.S. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011, 17(7):1649-1657.
135. Geller J., Albert J., Nachtsheim D., et al. Steroid levels in cancer of the prostate-markers of tumor differentiation and adequacy of anti-androgen therapy. Prog Clin Biol Res 1979, 33:103-111.
136. Labrie F., Dupont A., Bélanger A., et al. Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br J Urol 1989, 63(6):634-638.